James Marino - Onconova Therapeutics Independent Director
| ONTXDelisted Stock | USD 7.93 0.00 0.00% |
Director
James Marino is Independent Director of Onconova Therapeutics since 2015.
| Age | 68 |
| Tenure | 9 years |
| Phone | 267 759 3680 |
| Web | https://www.onconova.com |
Onconova Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3807) % which means that it has lost $0.3807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.843) %, meaning that it created substantial loss on money invested by shareholders. Onconova Therapeutics' management efficiency ratios could be used to measure how well Onconova Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Randal Chase | GeoVax Labs | 67 | |
| Matthew Sherman | Pulmatrix | 61 | |
| Richard Conley | Pulmatrix | 63 | |
| Kenneth Newport | Aeterna Zentaris | 48 | |
| Charles Mather | Tonix Pharmaceuticals Holding | 57 | |
| Steven Gillis | Pulmatrix | 65 | |
| Ernest Mario | Tonix Pharmaceuticals Holding | 79 | |
| Michael Cardiff | Aeterna Zentaris | N/A | |
| Tony Goodman | Adial Pharmaceuticals | 60 | |
| Akihisa Akao | Pulmatrix | 59 | |
| Arthur Elliott | Ibio Inc | 81 | |
| Kermit Anderson | Adial Pharmaceuticals | 67 | |
| Heath Cleaver | Bio Path Holdings | 42 | |
| John Richard | Vaxart Inc | 58 | |
| Scott Rocklage | Pulmatrix | 60 | |
| CPA CPA | Sonnet Biotherapeutics Holdings | 75 | |
| Juergen Ernst | Aeterna Zentaris | 77 | |
| Philip Russell | Ibio Inc | 85 | |
| James Treco | Tonix Pharmaceuticals Holding | 62 | |
| Bruce Daugherty | Tonix Pharmaceuticals Holding | 56 | |
| Dean Kollintzas | GeoVax Labs | 43 | |
Management Performance
| Return On Equity | -0.84 | |||
| Return On Asset | -0.38 |
Onconova Therapeutics Leadership Team
Elected by the shareholders, the Onconova Therapeutics' board of directors comprises two types of representatives: Onconova Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onconova. The board's role is to monitor Onconova Therapeutics' management team and ensure that shareholders' interests are well served. Onconova Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onconova Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henry Bienen, Director | ||
| Ramesh Kumar, Co-Founder, CEO and President and Director | ||
| Anne VanLent, Director | ||
| Ajay Bansal, CFO and Secretary | ||
| Premkumar Reddy, Founder, Lead Scientific Advisor and Director | ||
| Jerome Groopman, Director | ||
| James Marino, Independent Director | ||
| Manoj Maniar, Sr. VP of Product Devel. | ||
| Thomas McKearn, President - Research and Development | ||
| Abraham Oler, Vice President Corporate Development and General Counsel | ||
| Michael Hoffman, Chairman of the Board | ||
| Jack Stover, Director | ||
| Mark CPA, CFO COO | ||
| Victor MD, Chief Officer | ||
| Steven Fruchtman, Senior Vice President - Research and Development, Chief Medical Officer | ||
| Mark Guerin, Principal Accounting Officer and VP of Financial Planning and Accounting | ||
| Steven MD, President CEO | ||
| Mark MD, Chief Officer | ||
| Viren Mehta, Director | ||
| Adar Silverstein, Sr Devel |
Onconova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onconova Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.84 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (89.28) % | |||
| Current Valuation | (4.56 M) | |||
| Shares Outstanding | 21 M | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 7.95 % | |||
| Number Of Shares Shorted | 20.7 K | |||
| Price To Earning | (0.87) X | |||
| Price To Book | 1.43 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Onconova Stock
If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |